ATE149488T1 - Hiv-protease inhibitoren, verwendbar für die behandlung von aids - Google Patents

Hiv-protease inhibitoren, verwendbar für die behandlung von aids

Info

Publication number
ATE149488T1
ATE149488T1 AT93310357T AT93310357T ATE149488T1 AT E149488 T1 ATE149488 T1 AT E149488T1 AT 93310357 T AT93310357 T AT 93310357T AT 93310357 T AT93310357 T AT 93310357T AT E149488 T1 ATE149488 T1 AT E149488T1
Authority
AT
Austria
Prior art keywords
aids
protease inhibitors
hiv protease
treatment
inhibitors usable
Prior art date
Application number
AT93310357T
Other languages
German (de)
English (en)
Inventor
James Erwin Fritz
Marlys Hammond
Stephen Warren Kaldor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE149488T1 publication Critical patent/ATE149488T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60N-oxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93310357T 1992-12-22 1993-12-20 Hiv-protease inhibitoren, verwendbar für die behandlung von aids ATE149488T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/994,871 US5434265A (en) 1992-12-22 1992-12-22 Inhibitors of HIV protease

Publications (1)

Publication Number Publication Date
ATE149488T1 true ATE149488T1 (de) 1997-03-15

Family

ID=25541167

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93310357T ATE149488T1 (de) 1992-12-22 1993-12-20 Hiv-protease inhibitoren, verwendbar für die behandlung von aids

Country Status (24)

Country Link
US (2) US5434265A (US06534493-20030318-C00329.png)
EP (1) EP0604183B1 (US06534493-20030318-C00329.png)
JP (1) JPH07179417A (US06534493-20030318-C00329.png)
KR (1) KR940014335A (US06534493-20030318-C00329.png)
CN (1) CN1098407A (US06534493-20030318-C00329.png)
AT (1) ATE149488T1 (US06534493-20030318-C00329.png)
AU (1) AU667593B2 (US06534493-20030318-C00329.png)
BR (1) BR9305164A (US06534493-20030318-C00329.png)
CA (1) CA2112041A1 (US06534493-20030318-C00329.png)
CZ (1) CZ281693A3 (US06534493-20030318-C00329.png)
DE (1) DE69308514T2 (US06534493-20030318-C00329.png)
DK (1) DK0604183T3 (US06534493-20030318-C00329.png)
ES (1) ES2101252T3 (US06534493-20030318-C00329.png)
FI (1) FI935777A (US06534493-20030318-C00329.png)
GR (1) GR3023457T3 (US06534493-20030318-C00329.png)
HU (1) HUT70748A (US06534493-20030318-C00329.png)
IL (1) IL108091A (US06534493-20030318-C00329.png)
MX (1) MX9308005A (US06534493-20030318-C00329.png)
NO (1) NO301005B1 (US06534493-20030318-C00329.png)
NZ (1) NZ250492A (US06534493-20030318-C00329.png)
PL (1) PL301576A1 (US06534493-20030318-C00329.png)
TW (1) TW280813B (US06534493-20030318-C00329.png)
YU (1) YU79693A (US06534493-20030318-C00329.png)
ZA (1) ZA939476B (US06534493-20030318-C00329.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5679688A (en) 1992-03-11 1997-10-21 Narhex Limited Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE4439193A1 (de) * 1994-11-03 1996-05-09 Bayer Ag Mischung zur Korrosionshemmung von Metallen
US6222043B1 (en) 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
KR100490807B1 (ko) * 1995-11-28 2005-10-14 세파론, 인코포레이티드 시스테인및세린프로테아제의d-아미노산함유억제제
KR19980703369A (ko) * 1996-01-29 1998-10-15 후루따 다께시 카르보닐 화합물의 환원 방법
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
EP0900566A4 (en) 1996-12-27 2001-04-25 Japan Energy Corp NEW TRIPEPTIDE COMPOUNDS AND MEDICINES AGAINST AIDS
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6096778A (en) * 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
US6150378A (en) * 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
EP1095022A1 (en) * 1998-07-08 2001-05-02 G.D. Searle & Co. Retroviral protease inhibitors
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0558603B1 (en) * 1990-11-19 1998-08-26 Monsanto Company Retroviral protease inhibitors
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS

Also Published As

Publication number Publication date
ES2101252T3 (es) 1997-07-01
US5514802A (en) 1996-05-07
ZA939476B (en) 1995-06-19
US5434265A (en) 1995-07-18
NO301005B1 (no) 1997-09-01
HU9303680D0 (en) 1994-04-28
MX9308005A (es) 1994-08-31
DE69308514T2 (de) 1997-07-10
PL301576A1 (en) 1994-06-27
BR9305164A (pt) 1994-11-01
EP0604183A1 (en) 1994-06-29
CZ281693A3 (en) 1994-07-13
FI935777A (fi) 1994-06-23
CA2112041A1 (en) 1994-06-23
YU79693A (sh) 1997-07-31
AU667593B2 (en) 1996-03-28
AU5253093A (en) 1994-07-07
CN1098407A (zh) 1995-02-08
NO934718L (no) 1994-06-23
KR940014335A (ko) 1994-07-18
HUT70748A (en) 1995-10-30
NO934718D0 (no) 1993-12-20
EP0604183B1 (en) 1997-03-05
IL108091A (en) 1998-04-05
DK0604183T3 (da) 1997-05-26
TW280813B (US06534493-20030318-C00329.png) 1996-07-11
JPH07179417A (ja) 1995-07-18
NZ250492A (en) 1995-08-28
DE69308514D1 (de) 1997-04-10
IL108091A0 (en) 1994-04-12
GR3023457T3 (en) 1997-08-29
FI935777A0 (fi) 1993-12-21

Similar Documents

Publication Publication Date Title
ATE149488T1 (de) Hiv-protease inhibitoren, verwendbar für die behandlung von aids
NO934719D0 (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
DE69332002D1 (de) Hydroxyethylaminosulfonamide verwendbar als Inhibitoren retroviraler Proteasen
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
DE69329606D1 (de) 2,3-Bis-Carboxaamidomethyl substituierte Oxirane als Inhibitoren der HIV-Protease und ihre Verwendung zur Behandlung von AIDS Protease
RU93055683A (ru) Ингибиторы вич-протеазы, способ их получения, их использование, композиция
RU93055684A (ru) Соединения, ингибирующие вич-протеазу, способ их получения, фармацевтическая композиция, промежуточный продукт
DE69026991D1 (de) Phospholipide zur Behandlung der multiplen Sklerose
RU93055681A (ru) Ингибиторы вич-протеазы, способ их получения, их использование в фармкомпозициях